Skip to main content
Premium Trial:

Request an Annual Quote

GE Healthcare, Agilent

Premium
GE Healthcare introduced this week a new immunogenicity software package for its Biacore T100 label-free protein interaction analysis system.
 
The new system is to support screening, confirmation, and characterization of anti-drug antibodies during pre-clinical and clinical development. It enables the measurement of anti-drug antibodies in the presence of excess amounts of drugs.
 
Separately, the company also launched the ImageQuant TL SecurITy software and Installation Qualification and Operational Qualification protocols.
 
The ImageQuant software offers enhanced data security for analysis and documentation of 1D electrophoresis gels by ImageQuant TL, while IQOQ provides protocols for the ImageQuant 350 chemiluminescence, colorimetry, and fluorescence CCD imaging system, GE said in a statement.
 
The new products are designed to support the “increasingly stringent” requirements for laboratory data security and operational qualification for 1D electrophoresis gel analysis, the company said. 
 

 
Agilent Technologies launched its Bio-Monolith HPLC columns this week.
 
The columns provide high-resolution and rapid separations of large proteins, antibodies, plasmid DNA, viruses, phages, and other macro biomolecules, the company said in a statement.
 
The columns contain a short, polymer-based monolith disc, allowing for “flow-rate independent” separations. The monolith structure “virtually” eliminates diffusion as transport between mobile and stationary phase is rapid because there are no pores and no void volumes, Agilent said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more